Background and purpose. Nonalcoholic fatty liver disease (NAFLD) is the most common form of chronic liver
disease in paediatric population. NAFLD is related to excessive accumulation of hepatic
fat, and represents a spectrum of conditions ranging from fat accumulation alone (steatosis
without inflammation) to steatohepatitis (NASH) with macrovescicular steatosis in
hepatocytes associated with inflammation and fibrosis. Probiotics have been used to
prevent and treat inflammatory conditions of gastrointestinal tract. These therapeutic
effects might be related to a variety of direct and indirect mechanisms, including
modification of local microbiota, epithelial barrier function, intestinal inflammation,
or the immune system. Since probiotics modulatory effect on the gut flora could influence
the gut-liver axis, these microrganisms have been also proposed as possible adjunctive
therapy in some types of chronic liver disease. The aim of the present study was to
test the potential effect of the probiotic VSL#3 (a multistrain cocktail composed
of Streptococcus thermophilus and several species of Lactobacillus and Bifidobacteria) in an experimental model of NAFLD in young rat, identifying its anti-inflammatory
and anti-oxidative mechanisms.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Digestive and Liver DiseaseAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Identification
Copyright
© 2008 Published by Elsevier Inc.
